SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (1994)3/30/2000 10:02:00 PM
From: Jim Oravetz  Read Replies (1) of 2028
 
The Company accounts for all plans under APB Opinion No. 25, under which
no compensation cost has been recognized as all options granted during 1997,
1998 and 1999 have been granted at the fair market value of the Company's common
stock. Had compensation cost or these plans and the Company's 1998 ESPP been
determined in accordance with SFAS No. 123, the Company's net income and
EPS would have been reduced as follows:

Year Ended December 31,
-------------------------------------
1997 1998 1999
---- ---- ----
(in thousands except
per share data)

Net income: As reported ............ $ 14,478 $ 17,739 $ 13,862
Pro forma .............. 10,361 9,810 4,305

Basic EPS: As reported ............ $ 0.31 $ 0.37 $ 0.26
Pro forma 0.22 0.20 0.08

Diluted EPS: As reported ............ $ 0.28 $ 0.36 $ 0.26
Pro forma .............. 0.20 0.20 0.08

Under SFAS No. 123, the fair value of each option is estimated on the date
of grant using the Black Scholes option-pricing model with the following
weighted average assumptions used for grants in 1997, 1998 and 1999: (1)
expected life of option of seven years; (2) dividend yield of 0%; (3) expected
volatility of 64%, 56% and 58%; and (4) risk-free interest rate of 6.43%, 5.46%
and 5.66%, respectively.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext